Morales, PaulaBlasco-Benito, SandraAndradas, ClaraGómez Cañas, MaríaFlores, Juana MaríaGoya, PilarFernández-Ruiz, JavierSánchez, CristinaJagerovic, Nadine2024-01-172024-01-172015Morales P, Blasco-Benito S, Andradas C, Gómez-Cañas M, Flores JM, Goya P, Fernández-Ruiz J, Sánchez C, Jagerovic N. Selective, nontoxic CB(2) cannabinoid o-quinone with in vivo activity against triple-negative breast cancer. J MedChem. 2015, 58(5):2256-64.0022-26231520-480410.1021/acs.jmedchem.5b00078https://hdl.handle.net/20.500.14352/93638Triple-negative breast cancer (TNBC) represents a subtype of breast cancer characterized by high aggressiveness. There is no current targeted therapy for these patients whose prognosis, as a group, is very poor. Here, we report the synthesis and evaluation of a potent antitumor agent in vivo for this type of breast cancer designed as a combination of quinone/cannabinoid pharmacophores. This new compound (10) has been selected from a series of chromenopyrazole diones with full selectivity for the nonpsychotropic CB2 cannabinoid receptor and with efficacy in inducing death of human TNBC cell lines. The dual concept quinone/cannabinoid was supported by the fact that compound 10 exerts antitumor effect by inducing cell apoptosis through activation of CB2 receptors and through oxidative stress. Notably, it did not show either cytotoxicity on noncancerous human mammary epithelial cells nor toxic effects in vivo, suggesting that it may be a new therapeutic tool for the management of TNBCengjournal articlehttps://pubs.acs.org/doi/10.1021/acs.jmedchem.5b00078restricted access577.1Ciencias Biomédicas24 Ciencias de la Vida